Induction of MTG8-specific cytotoxic T-cell lines: MTG8 is probably a tumour antigen that is recognized by cytotoxic T cells in AML1-MTG8-fused gene-positive acute myelogenous leukaemia

British Journal of Haematology

Volumn 111, Issue 2, 2000, Pages 570-579

  Juncà, Jordi ^a   Flores, Alonso ^a   Granada, Maria Luisa ^a   Jiménez, Orlando ^a   Sancho, Juan M ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Acute myelogenous leukaemia (M2); Cytotoxic T cell line; HLA A0201 restriction; Minimal residual disease; MTG8

Indexed keywords

HLA ANTIGEN CLASS 1; PROTEIN MTG8; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY TITER; ARTICLE; CHROMOSOME 8; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE FUSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REMISSION;

ANTIGENS, NEOPLASM; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTOTOXICITY TESTS, IMMUNOLOGIC; DNA PRIMERS; DNA-BINDING PROTEINS; EPITOPES; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOCYTE ACTIVATION; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0034533215     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02400.x     Document Type: Article

References (36)

1. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation
2. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion
3. The detailed distribution of HLA-A, B, C antigens in normal human organs
4. Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR
5. Identification of two transcripts of AML1/ETO-fused gene in t (8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells
6. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells
7. Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. Use of analogues to orientate the matrix peptide in the HLA-A2 binding site
8. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
9. Study of circulating autoantibody to MTG8 protein associated with fusion gene of t (8;21) acute myeloid leukemia
10. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t (8;21) leukemia
11. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules
12. AML1/MTG8, fused gene of t (8;21) AML and clinical usefulness of MTG8 protein and circulating MTG8-autoantibody
13. Prevalence of antibodies against proteins derived from leukemia cells in patients with chronic myeloid leukemia
14. Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t (8;21) who acquired monosomy 17 during disease progression
15. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t (8;21) acute myelogenous leukemia
16. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript
17. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units
18. Clonal expansion of αβ-T lymphocytes with inverted Jβ1 bias in familial hemophagocytic lymphohistiocytosis
19. Dendritic cells stimulate the expansion of bcr abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia
20. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia
21. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission
22. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
23. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms
24. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients
25. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia
26. Recurring chromosome abnormalities in leukemia and lymphoma
27. Growth inhibition and induction of differentiation of t (8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8 (ETO)-specific antisense oligonucleotide
28. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids
29. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with 'curability' of experimental leukemia
30. In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy
31. Organization and sequences of the diversity, joining, and constant region genes of the human T-cell receptor beta chain
32. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells
33. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells
34. Transformation properties of the ETO gene, fusion partner in t(8:21) leukemias
35. Structure and expression of the human MTG8/ETO gene
36. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia